Literature DB >> 6382266

Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers.

I I Singer, D W Kawka, D M Kazazis, A W Alberts, J S Chen, J W Huff, G C Ness.   

Abstract

Mevinolin is a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase; EC 1.1.1.34), an enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis. We have been studying the hepatic distribution of reductase with immunofluorescence microscopy and liver ultrastructure with electron microscopy in normal and drug-treated rats. In control animals, only about 20% of the hepatocytes were reductase positive. These cells were localized in the periportal lobular zones. The numbers of positive hepatocytes in animals given mevinolin or cholestyramine (or both) were directly proportional to the activities of the HMG-CoA reductase determined biochemically. This induction of HMG-CoA reductase immunofluorescence was centered periportally. Rats given 0.075% mevinolin alone had a homogeneous distribution of reductase staining in their hepatocyte cytoplasm, whereas a combination of 0.25% mevinolin and 3% cholestyramine caused a 150-fold increase in enzyme activity and induced prominent juxtanuclear immunofluorescent globules of HMG-CoA reductase in all hepatocytes. With electron microscopy, these bodies were composed of tightly packed stacks of smooth endoplasmic reticulum cysternae and aggregates of branched smooth endoplasmic reticulum tubules. Our data suggest that a subpopulation of periportal rat hepatocytes may be uniquely specialized for cholesterol synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6382266      PMCID: PMC391745          DOI: 10.1073/pnas.81.17.5556

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Authors:  D J Chin; K L Luskey; R G Anderson; J R Faust; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

2.  Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

Authors:  H Mabuchi; T Haba; R Tatami; S Miyamoto; Y Sakai; T Wakasugi; A Watanabe; J Koizumi; R Takeda
Journal:  N Engl J Med       Date:  1981-08-27       Impact factor: 91.245

3.  Fluorescence microscopy: reduced photobleaching of rhodamine and fluorescein protein conjugates by n-propyl gallate.

Authors:  H Giloh; J W Sedat
Journal:  Science       Date:  1982-09-24       Impact factor: 47.728

4.  Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

Authors:  J A Tobert; G D Bell; J Birtwell; I James; W R Kukovetz; J S Pryor; A Buntinx; I B Holmes; Y S Chao; J A Bolognese
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

5.  Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase.

Authors:  J A Tobert; G Hitzenberger; W R Kukovetz; I B Holmes; K H Jones
Journal:  Atherosclerosis       Date:  1982-01       Impact factor: 5.162

6.  The effect of cholestyramine and Mevinolin on the diurnal cycle of rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Authors:  R D Tanaka; P A Edwards; S F Lan; E M Knöppel; A M Fogelman
Journal:  J Lipid Res       Date:  1982-09       Impact factor: 5.922

7.  Autoradiographic evidence for hepatic lobular concentration gradient of bile acid derivative.

Authors:  A L Jones; G T Hradek; R H Renston; K Y Wong; G Karlaganis; G Paumgartner
Journal:  Am J Physiol       Date:  1980-03

8.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

Authors:  A W Alberts; J Chen; G Kuron; V Hunt; J Huff; C Hoffman; J Rothrock; M Lopez; H Joshua; E Harris; A Patchett; R Monaghan; S Currie; E Stapley; G Albers-Schonberg; O Hensens; J Hirshfield; K Hoogsteen; J Liesch; J Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

9.  Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.

Authors:  P T Kovanen; D W Bilheimer; J L Goldstein; J J Jaramillo; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

10.  The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks.

Authors:  R Fears; D H Richards; H Ferres
Journal:  Atherosclerosis       Date:  1980-04       Impact factor: 5.162

View more
  28 in total

1.  Changes in activity and intra-acinar distribution of glucose-6-phosphate dehydrogenase and malic enzyme during pregnancy in rat liver.

Authors:  A P Newham; K Krieger; I P Maly; D Sasse
Journal:  Histochemistry       Date:  1991

2.  Heterogeneity of rat liver parenchyma in cholesterol 7 alpha-hydroxylase and bile acid synthesis.

Authors:  B Ugele; H J Kempen; J M Kempen; R Gebhardt; P Meijer; H J Burger; H M Princen
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

Review 3.  The use of primary cultures of adult rat hepatocytes to study induction of enzymes and DNA synthesis: effect of nafenopin and electroporation.

Authors:  S F Muakkassah-Kelly; F Bieri; F Waechter; P Bentley; W Stäubli
Journal:  Experientia       Date:  1988-10-15

Review 4.  Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.

Authors:  E E Slater; J S MacDonald
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Control of cholesterol synthesis through regulated ER-associated degradation of HMG CoA reductase.

Authors:  Youngah Jo; Russell A Debose-Boyd
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-06       Impact factor: 8.250

6.  Short- and long-term effects of biliary drainage on hepatic cholesterol metabolism in the rat.

Authors:  M J Smit; A M Temmerman; R Havinga; F Kuipers; R J Vonk
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

7.  Hepatic zonation of the formation and hydrolysis of cholesteryl esters in periportal and perivenous parenchymal cells.

Authors:  J R Romero; O Fresnedo; E Isusi; J Barrionuevo; B Ochoa
Journal:  Lipids       Date:  1999-09       Impact factor: 1.880

Review 8.  Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.

Authors:  J M Henwood; R C Heel
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

9.  Simvastatin and dipentyl phthalate lower ex vivo testicular testosterone production and exhibit additive effects on testicular testosterone and gene expression via distinct mechanistic pathways in the fetal rat.

Authors:  Brandiese E J Beverly; Christy S Lambright; Johnathan R Furr; Hunter Sampson; Vickie S Wilson; Barry S McIntyre; Paul M D Foster; Gregory Travlos; L Earl Gray
Journal:  Toxicol Sci       Date:  2014-07-23       Impact factor: 4.849

10.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.

Authors:  Clive R Pullinger; Celeste Eng; Gerald Salen; Sarah Shefer; Ashok K Batta; Sandra K Erickson; Andrea Verhagen; Christopher R Rivera; Sean J Mulvihill; Mary J Malloy; John P Kane
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.